EBITDA: Income before interest, taxes, depreciation and amortization.
Phathom Pharmaceuticals, Inc. (PHAT) had EBITDA of $-59.02M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$39.50M |
|
$-75.81M |
|
$5.04M |
|
$34.47M |
|
$99.43M |
|
$-59.92M |
|
$-15.89M |
|
$-75.81M |
|
$-75.81M |
|
$-75.81M |
|
$-75.81M |
|
$-75.81M |
|
$-75.81M |
|
$-59.92M |
|
|
EBITDA |
$-59.02M |
72.47M |
|
72.47M |
|
$-1.05 |
|
$-1.05 |
|
| Balance Sheet Financials | |
$218.88M |
|
$1.24M |
|
$31.34M |
|
$250.22M |
|
$91.82M |
|
$205.14M |
|
$564.23M |
|
$656.05M |
|
$-405.83M |
|
$-405.83M |
|
$-405.83M |
|
70.10M |
|
| Cash Flow Statement Financials | |
$-147.66M |
|
$-0.12M |
|
$0.08M |
|
$300.12M |
|
$152.43M |
|
$-147.69M |
|
$13.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.38 |
|
-- |
|
-- |
|
-1.02 |
|
-0.51 |
|
87.25% |
|
-151.69% |
|
-151.69% |
|
-- |
|
-191.91% |
|
-191.91% |
|
$-147.77M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
1.47 |
|
0.77 |
|
116.77 |
|
18.68% |
|
18.68% |
|
-30.30% |
|
37.77% |
|
$-5.79 |
|
$-2.04 |
|
$-2.04 |
|